Just caught something interesting in the biotech space - Tango Therapeutics stock absolutely popped yesterday, up over 36% after announcing a collaboration with Erasca on a cancer treatment combo study. The kind of move that gets people's attention.

Here's what's happening: Erasca is bringing their RAS inhibitor ERAS-0015 to the table, and they're pairing it with Tango's vopimetostat to test against MTAP-deleted RAS-mutant cancers. Basically, they're targeting two mechanisms at once to try to overcome treatment resistance in some really tough cancers - pancreatic and lung cancer specifically. The thinking is solid from a biology standpoint. Nearly all MTAP-deleted pancreatic cases have co-occurring RAS mutations, so hitting both pathways could actually work.

What caught my eye is the structure of the deal. Erasca provides the ERAS-0015 at no cost while Tango runs the phase I/II study. Both keep commercial rights to their own therapies. That's a smart risk-sharing arrangement for an early-stage combo.

Looking at Tango's bigger picture, they're still pre-commercial but moving things forward. They're gearing up for a pivotal study with vopimetostat monotherapy in pancreatic cancer next year. They also have another ongoing collaboration with Revolution Medicines testing similar combo approaches, with initial data expected in 2026. Their pipeline has a few other shots on goal too - TNG456 for glioblastoma and TNG260 being tested with Merck's Keytruda in lung cancer.

The stock's already up 147% over the past six months, so this collaboration is more of a validation of the direction they're heading rather than a surprise. Whether this becomes a real win depends on how the clinical data actually plays out. That's the usual story with biotech - promising biology on paper doesn't always translate to clinic. But the Erasca partnership shows other companies believe in the vopimetostat approach, which is worth noting.